Christopher Austin, Vesalius Therapeutics CEO (Flagship)

Flag­ship's lat­est boast? A start­up that will 'rev­o­lu­tion­ize treat­men­t' for 'nine­ty per­cent of hu­man ill­ness'

Christo­pher Austin has spent the last decade build­ing a gov­ern­ment agency known in part for help­ing change drug de­vel­op­ment for rare dis­eases. Now, he’d like to fo­cus on the far more com­mon ones.

On Wednes­day Austin and the VC firm Flag­ship Pi­o­neer­ing an­nounced the launch of — and a $75 mil­lion Se­ries A for — Vesal­ius Ther­a­peu­tics, a biotech that is try­ing to “rev­o­lu­tion­ize the treat­ment of the dis­eases that dri­ve nine­ty per­cent of hu­man ill­ness,” ac­cord­ing to a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.